Evenity (Romosozumab) and Rosuvastatin: What Women Need to Know About This Drug Combination

Does Romosozumab Interact With Rosuvastatin?

No clinically established pharmacokinetic drug-drug interaction exists between romosozumab (Evenity) and rosuvastatin. The two drugs work through entirely different pathways, and neither significantly inhibits or induces the other's metabolism. In practice, many postmenopausal women with severe osteoporosis also take a statin for cardiovascular protection, so this combination comes up often in clinical settings.

"no interaction" does not mean "take without thought." Romosozumab carries an FDA boxed warning for major adverse cardiovascular events (MACE), including myocardial infarction and stroke. Rosuvastatin is prescribed partly to reduce exactly those risks. Understanding how the two drugs sit alongside each other, and where the real monitoring priorities lie, matters for any woman taking both.

Why This Question Comes Up So Often

Severe osteoporosis and cardiovascular disease share overlapping risk factors in postmenopausal women. Estrogen loss accelerates both bone resorption and atherogenic lipid changes. Women in this group are frequently prescribed a statin for primary or secondary cardiovascular prevention alongside bone-targeted therapy. Approximately 12.6 million women in the United States have osteoporosis, and statin use in women over 55 is common enough that the overlap is the rule, not the exception.

What "No Pharmacokinetic Interaction" Actually Means

A pharmacokinetic interaction occurs when one drug changes the absorption, distribution, metabolism, or elimination of another. Romosozumab is a monoclonal antibody. Monoclonal antibodies are metabolized through proteolytic degradation into amino acids, not through cytochrome P450 enzymes or drug transporters. They do not inhibit or induce CYP enzymes. Rosuvastatin is metabolized minimally by CYP2C9 and is a substrate of the hepatic uptake transporters OATP1B1 and OATP1B3. Because romosozumab does not touch either pathway, the two drugs do not alter each other's blood levels.

How Each Drug Works: The Mechanisms Side by Side

Understanding the biology of each drug makes it clear why they don't interfere with each other pharmacokinetically, and why the cardiovascular dimension still requires attention.

Romosozumab (Evenity): Sclerostin Inhibitor

Romosozumab is a humanized monoclonal IgG2 antibody that binds and inhibits sclerostin, a protein produced by osteocytes that normally suppresses bone formation by blocking Wnt signaling. By neutralizing sclerostin, romosozumab simultaneously increases bone formation markers and decreases bone resorption markers. This dual anabolic-anticatabolic effect is unique among approved osteoporosis drugs.

The FRAME trial, published in the New England Journal of Medicine in 2016, randomized 7,180 postmenopausal women to romosozumab 210 mg subcutaneously monthly or placebo for 12 months, followed by denosumab in both groups. At 24 months, vertebral fracture risk was reduced by 75% compared with placebo. Lumbar spine bone mineral density increased by 13.3% at 12 months in the romosozumab group.

The treatment course is fixed: 12 monthly injections, then transition to antiresorptive therapy. There is no long-term maintenance dosing.

Rosuvastatin: HMG-CoA Reductase Inhibitor

Rosuvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol synthesis. Unlike lipophilic statins such as atorvastatin or simvastatin, rosuvastatin is hydrophilic. It enters hepatocytes primarily through active transport via OATP1B1 and OATP1B3 transporters, not through passive diffusion. This transporter-dependent uptake makes rosuvastatin sensitive to drugs that inhibit those transporters (such as cyclosporine, gemfibrozil, or certain HIV antiretrovirals), but romosozumab is none of those.

CYP2C9 accounts for a minor fraction of rosuvastatin metabolism. Drugs that strongly inhibit CYP2C9 (fluconazole, amiodarone) may raise rosuvastatin exposure modestly, but again, romosozumab has no CYP2C9 activity.

The Real Risk to Track: Cardiovascular Events and Muscle Safety

Romosozumab's Boxed Warning for Cardiovascular Events

The FDA added a boxed warning to Evenity's label after the ARCH trial (N=4,093 postmenopausal women with osteoporosis) compared romosozumab against alendronate. At 12 months, the romosozumab group had a higher rate of serious cardiovascular events: 2.5% versus 1.9% for alendronate. The absolute difference was small, but statistically meaningful enough for regulators to act.

The FDA label states that romosozumab should not be initiated in patients who have had a myocardial infarction or stroke within the preceding year. For a woman already on rosuvastatin for secondary cardiovascular prevention after a recent cardiac event, this contraindication is directly relevant. Her prescribers need to weigh whether romosozumab is the right anabolic agent, or whether teriparatide or abaloparatide (which lack this cardiovascular signal) would be safer choices.

A practical decision framework for postmenopausal women considering romosozumab who are also on a statin:

| Clinical situation | Recommendation | |---|---| | On statin for primary prevention, no prior MACE | Romosozumab generally appropriate; monitor cardiovascular symptoms | | Prior MI or stroke within 12 months | Romosozumab contraindicated per FDA label; consider teriparatide | | Prior MI or stroke more than 12 months ago | Discuss benefit-risk with cardiology; romosozumab not absolutely contraindicated but warrants shared decision-making | | Active statin myopathy workup in progress | Delay romosozumab initiation until CK and muscle symptoms are clarified |

Statin-Associated Muscle Symptoms (SAMS)

Statin myopathy is the most common reason women stop rosuvastatin. Observational studies estimate symptomatic muscle complaints in 5 to 10% of statin users, though the rate of true myositis (CK elevation to 10 times the upper limit of normal) is much lower, around 0.1%. Women may be at slightly higher risk of SAMS than men due to lower muscle mass per body weight, though the sex-specific data remains limited.

Romosozumab does not directly cause myopathy and does not alter rosuvastatin plasma concentrations. If muscle symptoms appear while a woman is taking both drugs, the statin is the more likely culprit. Standard workup applies: check serum creatine kinase, review rosuvastatin dose, assess for drug interactions with other medications the patient takes, and investigate thyroid function (hypothyroidism amplifies statin myopathy risk, and postmenopausal women have higher rates of subclinical hypothyroidism).

Life-Stage Context: Who Gets This Combination and Why It Matters

Postmenopausal Women: The Core Population

Romosozumab is FDA-approved specifically for postmenopausal women with osteoporosis at high or very high risk of fracture. This definition includes women with a prior osteoporotic fracture, a T-score of -2.5 or lower at the spine or hip, or a T-score of -1.0 or lower plus high FRAX fracture probability. This population overlaps heavily with the group for whom statins are prescribed.

Estrogen withdrawal at menopause drives a surge in bone turnover that can deplete 10 to 20% of bone mass in the first five years after the final menstrual period. The same hormonal shift worsens the lipid profile: LDL-C and triglycerides rise, HDL-C falls slightly. A woman entering her late 50s or 60s may therefore be starting both a bone-targeted drug and a statin for the first time within a few years of each other.

Perimenopause and Pre-Menopause: Not the Target Population

Romosozumab is not approved for premenopausal or perimenopausal women. Secondary osteoporosis in younger women (from glucocorticoid use, anorexia, primary ovarian insufficiency, or other causes) is managed through different pathways. The interaction question as framed applies almost exclusively to postmenopausal women.

Women With PCOS or Metabolic Disease

Women with PCOS frequently have dyslipidemia and may be on statins. If they develop glucocorticoid-induced or other forms of secondary osteoporosis later in life, romosozumab could theoretically be considered off-label, though this sits outside its approved use. Evidence in this specific subgroup is absent from the published literature, which is a gap worth naming.

Pregnancy, Lactation, and Contraception

Romosozumab is contraindicated in pregnancy. Sclerostin inhibition during skeletal development raises theoretical concerns about fetal bone growth, and animal reproduction studies showed fetal harm at doses that exceeded clinical exposure levels.

The FDA label assigns romosozumab to a category consistent with contraindication in pregnancy, and the label explicitly recommends advising women of reproductive potential to use effective contraception during treatment and for a period after the final dose. Given the 12-month treatment course and the antibody's half-life of approximately 6.4 days, the post-treatment washout period before conception can be considered with a clinician.

In practice, romosozumab's approved indication is postmenopausal women, so pregnancy is not a realistic concern for the vast majority of women receiving this drug. However, any woman of reproductive potential who is being considered for off-label use should discuss contraception explicitly before starting treatment.

Rosuvastatin is also contraindicated in pregnancy. Statins inhibit cholesterol synthesis, and cholesterol is necessary for fetal development. The FDA label for rosuvastatin states it is contraindicated during pregnancy and in nursing mothers. Women of reproductive potential on rosuvastatin should use reliable contraception, and if pregnancy is planned, rosuvastatin should be stopped before conception.

Neither drug should be used during breastfeeding. Data on romosozumab transfer into human milk are lacking. Rosuvastatin transfers into animal milk; human lactation data are insufficient to establish safety.

Monitoring and Practical Guidance for Women on Both Drugs

Before Starting Romosozumab

Your clinician should review your full cardiovascular history. If you have had a heart attack or stroke within the past 12 months, romosozumab is not appropriate. A baseline lipid panel and CK level are reasonable if not recently checked, particularly because statin dose adjustments may be under consideration. Calcium and vitamin D status should be assessed, as hypocalcemia is a contraindication to romosozumab and supplementation is expected during treatment.

During the 12-Month Treatment Course

Monthly injections mean monthly opportunities to check in. Report any new chest pain, shortness of breath, or neurological symptoms promptly. These could represent cardiovascular events that the FDA label warns about. Muscle pain or weakness, which is more likely attributable to rosuvastatin, should also be communicated rather than tolerated.

A serum calcium check in the first month is standard practice. Bone turnover markers (P1NP for formation, CTX for resorption) are sometimes tracked to confirm the drug is working, though this is not universally required.

After the 12-Month Course

Romosozumab must be followed by an antiresorptive agent or the bone gains made during treatment are rapidly lost. The Menopause Society (formerly NAMS) recommends sequential antiresorptive therapy after anabolic treatment to preserve BMD gains. Denosumab or a bisphosphonate are the typical next steps. Neither denosumab nor the commonly used bisphosphonates (alendronate, zoledronic acid) interact with rosuvastatin at a pharmacokinetic level.

Rosuvastatin Dose Considerations

The rosuvastatin prescribing information recommends a maximum starting dose of 5 mg daily in patients of Asian ancestry due to higher plasma concentrations. For most postmenopausal women taking romosozumab, rosuvastatin dose does not need adjustment on account of the bone drug. Any dose changes should be driven by lipid targets and tolerance, not by the combination with romosozumab.

What the Evidence Gap Looks Like for Women

Women were well-represented in the major romosozumab trials because the drug is approved exclusively for postmenopausal women. The FRAME trial and ARCH trial enrolled only postmenopausal women, so the fracture efficacy and safety data are, unusually for this field, entirely female. This is worth acknowledging.

The cardiovascular signal from ARCH has not been fully explained mechanistically. Sclerostin may have a role in vascular calcification; inhibiting it could theoretically affect vascular biology, though the data here are preliminary. A 2019 analysis published in JAMA Cardiology examined this question and found that the cardiovascular imbalance in ARCH was driven largely by the active-comparator design (romosozumab versus alendronate, not versus placebo), which complicates interpretation.

What is genuinely absent from the literature is any direct study of the romosozumab-rosuvastatin combination at a pharmacokinetic level. The conclusion that there is no interaction is based on mechanistic reasoning (different metabolic pathways, no shared enzymes or transporters) rather than a dedicated interaction study. That distinction is honest and clinically sufficient, but it is worth naming.

Who This Combination Is Right For, and Who Should Pause

Likely Appropriate

• Postmenopausal women with a T-score of -2.5 or lower, prior fragility fracture, or very high FRAX score who are on rosuvastatin for primary cardiovascular prevention and have no prior MACE in the past 12 months.
• Women who have tried bisphosphonates and had intolerance or inadequate BMD response, and need an anabolic agent.
• Women whose 10-year major osteoporotic fracture probability exceeds 20% by FRAX calculation, per National Osteoporosis Foundation guidance.

Requires Extra Caution or Reconsideration

• Women with a myocardial infarction or stroke within the past 12 months. The FDA label is direct: do not start romosozumab. Discuss teriparatide or abaloparatide with your clinician.
• Women with active statin myopathy or markedly elevated CK. Clarify the muscle situation before adding any new medication.
• Women with severe renal impairment (eGFR <30 mL/min), because rosuvastatin plasma concentrations rise significantly with renal dysfunction. The bone drug does not require renal dose adjustment, but the statin management becomes more complex.
• Women with uncorrected hypocalcemia, which is a contraindication to starting romosozumab regardless of other drugs.

Talking to Your Care Team

Two prescribers are often involved: the endocrinologist or rheumatologist managing osteoporosis and the primary care clinician or cardiologist prescribing the statin. A brief medication reconciliation confirming both drugs are on each provider's radar takes about two minutes and prevents duplicated monitoring or missed cardiovascular warnings.

Ask specifically: "Given my cardiovascular history, does romosozumab's boxed warning apply to me?" That single question, asked before the first injection, will open the right conversation. If you have had any cardiac event in the past year, the answer to that question changes the treatment plan.

Your pharmacist can also confirm, at the time of dispensing, that no pharmacy-level interaction flag is triggered by the combination. Major drug interaction databases (Lexicomp, Micromedex) do not list a clinically significant interaction between romosozumab and rosuvastatin, which aligns with the mechanistic reasoning above.